Has Rebecca Jones, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,061,887 in general payments to Rebecca Jones, MD across 1,069 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rebecca Jones, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rebecca Jones, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rebecca Jones, MD

Neurology · Phoenix, AZNPI 1104260819

Payments from drug & device makers

$1,061,887in general payments, 2019–2025

Across 1,069 payments — averaging $993.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$430K
Sanofi$379K
Genentech, Inc.$120K
TG Therapeutics, Inc.$57K
SK Life Science, Inc.$47K
Banner Life Sciences, LLC$15K
plus $15K from 53 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	114	$429,738
Sanofi	36	$378,656
Genentech, Inc.	20	$119,801
TG Therapeutics, Inc.	30	$56,688
SK Life Science, Inc.	11	$47,108
Banner Life Sciences, LLC	85	$14,587
AbbVie(2 entities)	179	$3,101
Biogen	94	$1,569
AstraZeneca	33	$1,320
UCB, Inc.	75	$1,261
Genentech USA, Inc.	27	$834
Teva Pharmaceuticals USA, Inc.	25	$754
Pfizer	39	$653
Bristol Myers Squibb	26	$530
Amneal Pharmaceuticals LLC	31	$502
EMD Serono, Inc.	16	$478
Lilly USA, LLC	29	$454
Neurocrine Biosciences, Inc.	19	$450
Amgen(2 entities)	18	$337
Eisai Inc.	13	$300
Argenx US, Inc.	10	$280
Acorda Therapeutics, Inc	21	$276
Cycle Pharmaceuticals Inc	12	$193
Acadia Pharmaceuticals Inc	9	$184
Lundbeck LLC	8	$169
Johnson & Johnson	13	$167
Merz Pharmaceuticals, LLC	5	$147
Ipsen Biopharmaceuticals, Inc	5	$137
Biohaven Pharmaceutical Holding Company Ltd.	10	$126
Abbott	4	$99
Otsuka America Pharmaceutical, Inc.	4	$93
Medtronic	3	$77
Sunovion Pharmaceuticals Inc.	3	$59
Catalyst Pharmaceuticals, Inc.	3	$56
Vanda Pharmaceuticals Inc.	2	$51
Alnylam Pharmaceuticals Inc.	3	$47
Impel Pharmaceuticals Inc.	2	$44
Takeda Pharmaceuticals U.S.A., Inc.	2	$43
Upsher-smith Laboratories LLC	2	$42
ANI Pharmaceuticals, Inc.	2	$40
CSL Behring	1	$40
Boston Scientific	2	$37
Mylan Specialty L.p.	1	$34
Kyowa Kirin, Inc.	2	$34
Grifols USA, LLC	2	$33
Neurelis, Inc.	2	$30
Vertical Pharmaceuticals, LLC	2	$27
Mallinckrodt Hospital Products Inc.	2	$26
Corium, LLC	2	$25
Tanabe Pharma America, Inc.	1	$21
Xeris Pharmaceuticals, Inc.	1	$20
Sumitomo Pharma America, Inc.	1	$17
Neuropace, Inc.	1	$15
Supernus Pharmaceuticals, Inc.	1	$14
Arbor Pharmaceuticals, Inc.	1	$13
Assertio Therapeutics, Inc.	1	$13
Bausch Health US, LLC	1	$12
Biohaven Pharmaceuticals, Inc.	1	$12
Collegium Pharmaceutical, Inc.	1	$12

How this compares

$1,061,887 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Medicare billing

Part B allowed, 2024

$180,149

Medicare patients

314

Services billed

11,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Phoenix

David WeidmanPhoenix$7.4M
Stephen FlitmanPhoenix$4.4M
Barry HendinPhoenix$4.4M
Jeremy ShefnerPhoenix$3M
Danielle CabralPhoenix$2.8M
Suraj MuleyPhoenix$2.8M
Todd SchwedtPhoenix$2.8M
Todd LevinePhoenix$2.7M
Anna BurkePhoenix$2.2M
Maria OspinaPhoenix$2.1M

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →